Abstract
Secondary hematologic malignancies, such as B-cell acute lymphoblastic leukemia/lymphoma (B-ALL), have been reported following multiple myeloma. Tyrosine kinase inhibitors have improved clinical outcomes of patients with Philadelphia-positive (Ph+) B-ALL. Therefore, recognition of the Ph chromosome in B-ALL patients is important for both prognosis and therapies. We present a case of a secondary Ph+ B-ALL following multiple myeloma that highlights a BCR::ABL1 fusion by a gene fusion assay to reveal a cryptic Ph chromosome, which may otherwise be missed by conventional cytogenetics and typical interphase fluorescence in situ hybridization.
Original language | English (US) |
---|---|
Pages (from-to) | 30-32 |
Number of pages | 3 |
Journal | Cancer Genetics |
Volume | 274-275 |
DOIs | |
State | Published - Jun 2023 |
Keywords
- B-cell acute lymphoblastic leukemia/lymphoma
- Fluorescence in situ hybridization
- Gene fusion assay
- Karyotype
- Multiple myeloma
- Philadelphia-positive
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Genetics
- Molecular Biology
- Cancer Research